Organon (OGN) Shares Outstanding (2020 - 2026)
Organon (OGN) posted quarterly Shares Outstanding (Entity) of $262.6 million for Q2 2026, up 1.02% year-over-year from $260.0 million in Q2 2025, and little changed on a QoQ basis from $262.6 million in Q1 2026.
Organon (OGN) Shares Outstanding (2020 - 2026) Analysis & Trends
Organon has reported Shares Outstanding (Entity) for 7 years, with the latest figure at $262.6 million in Q2 2026.
- Shares Outstanding (Entity) for Q2 2026 came in at $262.6 million, up 1.02% year-over-year; the trailing twelve-month figure through Jun 2026 was $262.6 million (up 1.02% YoY), and the FY2025 annual result was $260.3 million, up 0.98% from the prior year.
- Shares Outstanding (Entity) was little changed at $262.6 million in Q2 2026, from $262.6 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $262.6 million in Q1 2026 and troughed at $253.6 million in Q1 2022.
- A 5-year average of $257.2 million and a median of $256.7 million in 2024 frame the typical range for Shares Outstanding (Entity).
- The widest annual swing landed in 2022, when Shares Outstanding (Entity) increased 0.05%; it then advanced 1.82% in 2026.
- A 5-year view of Shares Outstanding (Entity) shows it stood at $254.4 million in 2022, then grew by 0.49% to $255.6 million in 2023, then gained by 0.85% to $257.8 million in 2024, then increased by 0.98% to $260.3 million in 2025, then grew by 0.88% to $262.6 million in 2026.
- Per Business Quant data, the three most recent Shares Outstanding (Entity) figures were $262.6 million in Q2 2026, $262.6 million in Q1 2026, and $260.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 2.41 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.77 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 2.47 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 1.91 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 1.55 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 540.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 1.24 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 5.70 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 2.03 Bn |
| 10 | Organon | 3.61 Bn | 2.48 Bn | 847.00 Mn | 262.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 262.61 Mn |
| Mar 31, 2026 | 260.37 Mn |
| Dec 31, 2025 | 259.50 Mn |
| Sep 30, 2025 | 259.98 Mn |
| Jun 30, 2025 | 259.94 Mn |
| Mar 31, 2025 | 257.86 Mn |
| Dec 31, 2024 | 257.05 Mn |
| Sep 30, 2024 | 257.50 Mn |
| Jun 30, 2024 | 257.29 Mn |
| Mar 31, 2024 | 255.70 Mn |
| Dec 31, 2023 | 255.24 Mn |
| Sep 30, 2023 | 255.59 Mn |
| Jun 30, 2023 | 255.34 Mn |
| Mar 31, 2023 | 254.39 Mn |
| Dec 31, 2022 | 254.08 Mn |
| Sep 30, 2022 | 254.35 Mn |
| Jun 30, 2022 | 254.02 Mn |
| Mar 31, 2022 | 253.58 Mn |
| Dec 31, 2021 | 253.54 Mn |
| Sep 30, 2021 | 253.53 Mn |